RxDoctor Payments Data

Deborah Meester, MD

Family Medicine · Vernon, NYNPI 1750342226

Payments from drug & device makers

$1,063in general payments, 2019–2025

Across 65 payments — averaging $16.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$260
  • AstraZeneca$176
  • E.r. Squibb & Sons, L.L.C.$135
  • Lilly USA, LLC$133
  • AbbVie$127
  • Novo Nordisk$76
  • plus $156 from 6 others

What the payments were for

  • Food & beverage$1,063100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,063 in reported general payments places this provider in the 65th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$122,178
Medicare patients
298
Services billed
1,709

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide77$77,649
EliquisApixaban37$44,149
XareltoRivaroxaban31$37,574
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$34,348
FarxigaDapagliflozin Propanediol30$32,747
MounjaroTirzepatide26$32,680
TrulicityDulaglutide18$31,895
Breo ElliptaFluticasone/Vilanterol22$20,054
InvokanaCanagliflozin13$19,800
JardianceEmpagliflozin14$14,165
MyrbetriqMirabegron11$13,509
ShingrixVaricella-Zoster Ge/As01b/Pf38$8,460
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$6,089
Combivent RespimatIpratropium/Albuterol Sulfate11$5,293
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$4,844

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$76$77,64977 claims
Lilly USA, LLCMounjaro, Trulicity$133$64,57444 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$68$62,862105 claims
PfizerEliquis$260$44,14937 claims
AstraZenecaFarxiga$176$32,74730 claims
Boehringer IngelheimJardiance, Combivent Respimat$16$19,45925 claims
AbbVieSynthroid$127$92815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,321 family medicine providers in New York.

Other family medicine in Vernon

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →